January 22, 2021 -- Ten of the world's largest biopharmaceutical companies publicly launched a new nonprofit corporation, Accumulus Synergy. The aim is to support interactions between industry and global health authorities to enable real-time collaboration and data exchange.
Accumulus was formed on July 13, 2020, to provide a common platform to share data with the goal of making the regulatory process more efficient by leveraging advanced technology and tools for data exchange. Secondarily, the platform should help reduce the cost of innovation and ultimately bring patients new safe and effective medicines faster.
The initial members of Accumulus include Amgen, Astellas, Bristol Myers Squibb, GlaxoSmithKline (GSK), the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), Eli Lilly, Pfizer, Roche, Sanofi, and Takeda. These companies have provided funding to support the platform and initial applications.
Accumulus plans to consult with the Japanese Pharmaceutical and Medical Devices Agency, the European Medicines Agency, the U.K. Medicines and Healthcare products Regulatory Agency, and the U.S. Food and Drug Administration, among other agencies worldwide.